Risankizumab对中重度UC或CD患者CYP450底物药代动力学影响的评估
该研究在中重度活动性克罗恩病或溃疡性结肠炎患者(n=20)中,采用鸡尾酒法评估risankizumab对CYP1A2、CYP2C9、CYP2C19、CYP2D6和CYP3A底物药代动力学的影响。结果显示,除咖啡因和奥美拉唑外,各探针底物的Cmax和AUCinf比值大多在0.8-1.25等效界内,奥美拉唑代谢物5-羟基奥美拉唑暴露在治疗前后相当,总体表明risankizumab对上述CYP酶无临床相关影响。
要点
- Risankizumab对CYP1A2、CYP2C9、CYP2C19、CYP2D6和CYP3A底物总体无临床相关影响。
- 咖啡因AUCinf的90%CI上限超1.25,但点估计仅1.13,Cmax比值在等效界内。
- 奥美拉唑AUCt和AUCinf的90%CI下限略低于0.8,但其CYP2C19代谢物暴露前后相当。
核心结论
- 总体数据表明risankizumab对中重度CD或UC患者评估的CYP酶无临床相关影响。
研究设计与样本
- 在中重度活动性CD或UC患者(n=20)中开展的鸡尾酒法药物相互作用研究。
- 患者每4周静脉输注risankizumab 1800 mg,共4次,前后分别给予CYP探针底物。
- 探针底物包括咖啡因100 mg(CYP1A2)、华法林10 mg(CYP2C9)、奥美拉唑20 mg(CYP2C19)、美托洛尔50 mg(CYP2D6)和咪达唑仑2 mg(CYP3A)。
主要发现
- 除奥美拉唑和咖啡因外,各CYP探针底物的Cmax和AUCinf比值点估计及90%CI大多在0.8-1.25等效界内。
- 咖啡因AUCinf的90%CI上限超过1.25,但点估计为1.13,Cmax比值在0.8-1.25内。
- 奥美拉唑AUCt(90%CI下限0.715)和AUCinf(90%CI下限0.624)略低于等效下限,但5-羟基奥美拉唑暴露前后相当。
- 本研究未发现新的安全性问题。
关键数值与推荐
- 等效性判定采用0.8-1.25的默认等效界。
- 咖啡因AUCinf比值点估计1.13,90%CI上限超1.25。
- 奥美拉唑AUCt的90%CI下限0.715,AUCinf的90%CI下限0.624。
临床怎么用
- 基于本研究数据,risankizumab与经上述CYP酶代谢的药物合用时,预期无需因CYP酶抑制而调整剂量。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND OBJECTIVE: The objective of this study was to characterize the effects of risankizumab on the pharmacokinetics of cytochrome P450 (CYP) 1A2, CYP2C9, CYP2C19, CYP2D6, and CYP3A substrates in patients with moderately to severely active Crohn's disease (CD) or ulcerative colitis (UC) using a cocktail approach. METHODS: Patients with CD or UC (n = 20) received single doses of probe substrates for CYP1A2 (caffeine 100 mg), CYP2C9 (warfarin 10 mg), CYP2C19 (omeprazole 20 mg), CYP2D6 (metoprolol 50 mg), and CYP3A (midazolam 2 mg) before and after intravenous infusions of risankizumab 1800 mg once every 4 weeks for four doses. Serial blood samples were collected for determination of concentrations of the CYP probe drugs and metabolites with and without risankizumab. Trough samples for risankizumab were collected at sparse timepoints. RESULTS: The point estimates and 90% confidence intervals for maximum plasma concentration (Cmax) and the area under the plasma concentration-time curve from time zero to infinity (AUCinf) ratios for the CYP probe substrates administered with risankizumab versus without risankizumab were mostly within the 0.8-1.25 equivalence bounds, except for omeprazole and caffeine. While the upper 90% CI for caffeine AUCinf exceeded 1.25, the point estimate was a modest 1.13 and the Cmax ratio was well within 0.8-1.25. For omeprazole, while the lower bound of the 90% CI for AUCt (0.715) and AUCinf (0.624) extended slightly below the default equivalence limit, the exposures of its metabolite, 5-hydroxy-omeprazole, formed via CYP2C19, were comparable before and after risankizumab treatment, indicating a limited impact of risankizumab. No new safety issues were identified in this study. CONCLUSION: The totality of data indicated a lack of clinically relevant impact of risankizumab on the evaluated CYP enzymes in patients with CD/UC. CLINICALTRIALS: GOV: NCT04254783.
引用
- D'Cunha R, Azam T, Kalabic J, et al. Evaluation of the Effect of Risankizumab on the Pharmacokinetics of Cytochrome P450 Substrates in Patients with Moderately to Severely Active Ulcerative Colitis or Crohn's Disease. Clin Pharmacokinet. 2024. PMID: 39707077. doi:10.1007/s40262-024-01462-4
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。